Corneal implants get FDA approval

Article

Addition Technology, Inc., the maker of Intacs corneal implants, AlphaSphere orbital implants and the AlphaCor artificial cornea has received FDA approval for an expanded range of additional sizes of Intacs corneal implants for keratoconus.

Addition Technology, Inc., the maker of Intacs corneal implants, AlphaSphere orbital implants and the AlphaCor artificial cornea has received FDA approval for an expanded range of additional sizes of Intacs corneal implants for keratoconus.

“The availability of the larger sizes in the US expands its use when treating keratoconus patients. In my practice, where we manage over 1,000 keratoconic patients, I can definitely see a broader subsection of patients benefiting from these new Intacs sizes,” said Dr Yaron Rabinowitz, Director of eye research at the Cedar Sinai Medical Center, Los Angeles, and clinical professor of ophthalmology, University California, Los Angeles. “I have been pleased with the results and now see this as an additional option to delay or avoid a corneal transplant for keratoconic patients.”

Dr David Schanzlin, of Shiley Eye Clinic in California is one of the original FDA medical monitors and first US surgeon to work with Intacs for keratoconus pioneer Prof. Joseph Colin, said: “Our colleagues in Europe have been presenting data for over 10 years regarding the benefits of the larger sizes. Based on the impressive results they have reported, I view this as an important breakthrough in addressing keratoconus, particularly in younger people where a transplant may not always be the first option.”

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
© 2025 MJH Life Sciences

All rights reserved.